Skip to content

Ultrasound Guided Quadratus Lumborum Block for Postoperative Pain in Abdominoplasty

Ultrasound Guided Quadratus Lumborum Block for Postoperative Pain in Abdominoplasty: A Randomized Controlled Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02932930
Enrollment
40
Registered
2016-10-13
Start date
2016-10-31
Completion date
2019-08-31
Last updated
2019-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

QLB, Abdominoplasty, Quadratus lumborum block

Brief summary

The original concept of a quadratus lumborum block (QLB) indicated for analgesia after abdominal surgery was first described by Blanco in 2007. Also referred to as a posterior transversus abdominis plane (TAP) block, the QLB consists in deposition of local anesthetic on either the posterior or the anterolateral border of the quadratus lumborum muscle. TAP blocks have already been proved effective in urologic, abdominal, and gynecologic procedures by blocking the sensory nerve supply to the anterior abdominal wall thus reducing the amount of postoperative analgesic medication. The main advantages of QLB compared to the TAP block is a wider sensory block area and a longer duration of analgesia. This is due to the extension of local anesthetic agents beyond the TAP plane to the thoracic paravertebral space(4). Previous reports have shown that QLB is effective in providing pain relief after various abdominal operations. However, there are no published reports on QLB for postoperative pain after abdominoplasty. This prospective, randomized, double-blinded, controlled study aims to evaluate the analgesic efficacy, opioids consumption and quality of recovery of QLB in patients undergoing abdominoplasty. Patients scheduled to have abdominoplasty will be randomized to receive bilateral QLB with either ropivacaine 0.2% or normal saline. Post-operative cumulative analgesic medication consumption, pain severity at rest and on movement, as well as quality of recovery will be evaluated and compared in both groups.

Interventions

PROCEDUREQLB bloc

0,2ml/kg of 0,2% ropivacaine

DRUG0.9% normal saline

0,2ml/kg of 0.9% normal saline

Sponsors

St Joseph University, Beirut, Lebanon
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

1. Standard abdominoplasty procedure 2. Written informed consent 3. Age ≥ 18 years 4. Female

Exclusion criteria

1. Patient's refusal 2. Allergies to any study medication 3. Inability to comprehend or participate in scoring scales 4. Deformations that could possibly affect the spread of the local anesthetic in the quadratus lumborum muscle plane 5. Quadratus lumborum muscle plane not seen in ultrasound examination 6. Coagulopathy or on anticoagulants

Design outcomes

Primary

MeasureTime frameDescription
Cumulative morphine consumptionup to 48 hourCumulative morphine consumption in mg while in the PACU and tramadol dose till 48 hour post operatively.

Secondary

MeasureTime frameDescription
Postoperative pain severityup to 48 hourPostoperative pain severity in Numerical Rating Scale at rest in the first 48 hour after surgery. Ranging from 0 for no pain to 10 for worst pain imaginable. All patients will be assessed postoperatively by a blinded investigator: at 2, 4, 6, 12, 24, 36, and 48 hour postoperatively.
Postoperative dynamic pain severityup to 48 hourPostoperative dynamic pain severity (walking, coughing, deep breathing) in Numerical Rating Scale in the first 48 hour after surgery. Ranging from 0 for no pain to 10 for worst pain imaginable. All patients will be assessed postoperatively by a blinded investigator: at 2, 4, 6, 12, 24, 36, and 48 hour postoperatively.
Nausea or vomitingup to 48 hourNausea or vomiting up to 48h post operatively (2, 4, 6, 12, 24, 36, and 48 hour postoperatively) using the following four grades scale: 0 = No nausea; 1 = Mild nausea; 2 = Moderate nausea; 3 = Severe nausea or vomiting
Time to first tramadol doseup to 48 hourTime to first tramadol dose: time from the discharge to the surgical ward to the first postoperative subcutaneous tramadol dose requested by the patient.
Quality of recoveryup to 48 hourQuality of recovery using the self-assessment quality of recovery (QoR) scale to assess the patient's recovery quality
Time to first walkup to 48 hourTime to first walk
Sedation levelup to 48 hourSedation level up to 48 hour post operatively using the following Ramsay score.

Countries

Lebanon

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026